Skip to content
Home/Companies/MedTech/Avedro

Avedro

MedTech·US·Exited 2019·Held 5yr
Entry
2014
Hold
5yr
Exit
2019

Who owns Avedro?

Avedro is an American MedTech company, now owned by Glaukos, which acquired it in 2019 from Abingworth.

Hand-verified · updated 2026-05-21

Open JSON · CC-BY
Abingworth
Investor
Abingworth
Abingworth Bioventures VI · 2014 · Life Sciences VC

Key facts

HQUS
SectorMedTech
StatusAcquired
Exit Type
Trade Sale
Buyer
Glaukos
Exit Year
2019

More from Abingworth Bioventures VI

Other portfolio companies in the same fund.

Verona Pharma
Verona Pharma
Exited 2025
BiotechUK
to Merck & Co.
Venatorx Pharmaceuticals
Venatorx Pharmaceuticals
Active
HealthcareUS· 2022
Exicure
Active
BiotechUS· 2019
Soleno Therapeutics
Soleno Therapeutics
Exited 2026
BiotechUS· 2018
to Neurocrine Biosciences
Tizona Therapeutics
Tizona Therapeutics
Active
BiotechUS· 2016
Median Technologies
Active
MedTechFrance· 2015

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns Avedro?

Avedro is now owned by Glaukos, which acquired it in 2019 from Abingworth.

When did Glaukos acquire Avedro?

Glaukos acquired Avedro in 2019, buying from Abingworth.

Who did Avedro sell to?

Abingworth sold Avedro to Glaukos in 2019 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue